Display options
Cite
Doğan Bulut S, Bulut S, Tüzer V, et al. The Effects of Prolactin-Raising and Prolactin-Sparing Antipsychotics on Prolactin Levels and Bone Mineral Density in Schizophrenic Patients. Noro Psikiyatr Ars. 2014;51(3):205-210doi: 10.4274/npa.y6628.
Doğan Bulut, S., Bulut, S., Tüzer, V., Ak, M., Ak, E., Kisa, C., Aydemir, �. �., & Göka, E. (2014). The Effects of Prolactin-Raising and Prolactin-Sparing Antipsychotics on Prolactin Levels and Bone Mineral Density in Schizophrenic Patients. Noro psikiyatri arsivi, 51(3), 205-210. https://doi.org/10.4274/npa.y6628
Doğan Bulut, Süheyla, et al. "The Effects of Prolactin-Raising and Prolactin-Sparing Antipsychotics on Prolactin Levels and Bone Mineral Density in Schizophrenic Patients." Noro psikiyatri arsivi vol. 51,3 (2014): 205-210. doi: https://doi.org/10.4274/npa.y6628
Doğan Bulut S, Bulut S, Tüzer V, Ak M, Ak E, Kisa C, Aydemir Ç, Göka E. The Effects of Prolactin-Raising and Prolactin-Sparing Antipsychotics on Prolactin Levels and Bone Mineral Density in Schizophrenic Patients. Noro Psikiyatr Ars. 2014 Sep;51(3):205-210. doi: 10.4274/npa.y6628. Epub 2014 Sep 01. PMID: 28360627; PMCID: PMC5353124.
Copy Download .nbib Format: NLM
Share it on

Noro Psikiyatr Ars. 2014 Sep;51(3):205-210. doi: 10.4274/npa.y6628. Epub 2014 Sep 01.

The Effects of Prolactin-Raising and Prolactin-Sparing Antipsychotics on Prolactin Levels and Bone Mineral Density in Schizophrenic Patients.

Noro psikiyatri arsivi

Süheyla Doğan Bulut, Serdar Bulut, Verda Tüzer, Mehmet Ak, Emine Ak, Cebrail Kisa, Çiğdem Aydemir, Erol Göka

Affiliations

  1. Clinic of Psychiatry, Gazi Mustafa Kemal State Hospital, Ankara, Turkey.
  2. Clinic of Psychiatry, Etimesgut Military Hospital, Ankara, Turkey.
  3. Clinic of Psychiatry, Ankara Numune Training and Research Hospital, Ankara, Turkey.
  4. Clinic of Psychiatry, Gülhane Military Medical Academy, Ankara, Turkey.
  5. Clinic of Psychiatry, Kilis State Hospital, Kilis, Turkey.
  6. Department of Psychiatry, Konya Selçuk University, Meram Faculty of Medicine, Konya, Turkey.

PMID: 28360627 PMCID: PMC5353124 DOI: 10.4274/npa.y6628

Abstract

INTRODUCTION: We aimed to investigate the effects of antipsychotics on prolactin levels in patients diagnosed with schizophrenia and the effects of hyperprolactinemia on bone mineral density (BMD) in patients on long-term antipsychotics.

METHOD: In this study, we included eighty consecutive patients who were diagnosed with schizophrenia according to DSM-IV, had been using the same antipsychotic for the last ten months, and fulfilled the inclusion criteria. Data on sociodemographic characteristics of the patients were collected through an information sheet. The Scale for the Assessment of Negative Symptoms (SANS) and the Scale for the Assessment of Positive Symptoms (SAPS) were used to rate positive and negative symptoms of the patients. In addition, their body mass indices (BMI) were calculated. Prolactin levels were measured through luminescence immune assay and BMD measurements were made at lumbar and femoral sites using dual-energy x-ray absorbtiometry. Haloperidol (n=20) and risperidone (n=20) were assigned to prolactin-raising antipsychotic group, and olanzapine (n=20) and quetiapine (n=20) were assigned to prolactin-sparing antipsychotic group for this study. The effects of antipsychotics on BMD were compared among these groups.

RESULTS: Hyperprolactinemia was determined in 60% of haloperidol using patients, 90% of risperidone using patients, 25% of olanzapine using patients and 10% of quetiapine using patients. Mean prolactin levels were found to be significantly higher in prolactin-raising antipsychotic using group (p<0.001). There were no statistically significant differences in BMD values between the two groups, for the sites where the measurement was done. Lumbar spine and femoral neck T-scores and Z-scores in the prolactin-raising group significantly negatively correlated with the treatment durations and chlorpromazineequivalent doses (p<0.05). BMI and BMD values of both groups also displayed statistically significant positive correlations (p<0.05).

CONCLUSION: The statistically significant differences in mean prolactin levels and numbers of patients with hyperprolactinemia between the treatment groups support the validity of classifying the antipsychotics as prolactin-raising and prolactin-sparing". The relationship of BMD with the treatment duration and doses in the prolactin-raising antipsychotic using group was deemed to be important, since it indicated that a decrease in BMD was to be expected in long-term antipsychotic treatment.

Keywords: Schizophrenia; antipsychotic; bone mineral density; prolactin-raising

Conflict of interest statement

Conflict of Interest: The authors reported no conflict of interest related to this article. Çıkar Çatışması: Yazarlar bu makale ile ilgili olarak herhangi bir çıkar çatışması bildirmemişlerdir.

References

  1. Ann N Y Acad Sci. 2004 Dec;1032:297-8 - PubMed
  2. Calcif Tissue Int. 1999 May;64(5):380-3 - PubMed
  3. Am J Psychiatry. 2003 Sep;160(9):1618-20 - PubMed
  4. Am J Psychiatry. 2005 Jan;162(1):162-7 - PubMed
  5. J Clin Psychopharmacol. 2005 Feb;25(1):26-31 - PubMed
  6. Clin Ther. 2000 Sep;22(9):1085-96 - PubMed
  7. J Clin Psychopharmacol. 1999 Feb;19(1):57-61 - PubMed
  8. Am J Psychiatry. 1999 Feb;156(2):286-93 - PubMed
  9. Psychiatry Investig. 2010 Dec;7(4):278-84 - PubMed
  10. N Engl J Med. 1980 Dec 25;303(26):1511-4 - PubMed
  11. Endocrinol Metab Clin North Am. 1988 Mar;17(1):213-23 - PubMed
  12. J Psychopharmacol. 2012 May;26(5 Suppl):42-51 - PubMed
  13. Endocr Pract. 1997 Jul-Aug;3(4):209-13 - PubMed
  14. Psychoneuroendocrinology. 2003 Apr;28 Suppl 2:97-108 - PubMed
  15. J Clin Psychiatry. 2006 Sep;67(9):1391-6 - PubMed
  16. Br J Psychiatry. 2004 Jun;184:503-8 - PubMed
  17. Br J Psychiatry. 2002 Jul;181:49-55 - PubMed
  18. Psychosom Med. 1995 Sep-Oct;57(5):485-91 - PubMed
  19. Clin Exp Pharmacol Physiol. 1992 Sep;19(9):603-6 - PubMed
  20. J Clin Psychiatry. 2002 May;63(5):408-13 - PubMed
  21. Psychoneuroendocrinology. 2003 Apr;28 Suppl 2:55-68 - PubMed

Publication Types